Regenerative Therapies Market, By Tissue Type (Allograft, Xenograft, Alloplast), By Application type (Soft Tissue Repair, Cardiovascular, Dental, Orthoped, CNS disease treatment,Others), By End user (Hospitals, Ambulatory Surgical Centers, Educational Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jun 2023

Code : CMI3712

Pages :178

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Regenerative Therapies Market: Key Developments

Regenerative medicine is diversifying its applications beyond tissue repair and wound care, extending into fields such as cardiology, neurology, oncology, and more. Companies are actively conducting clinical trials to establish their dominance by introducing innovative products and therapies, disrupting traditional treatment methods.

In June 11, 2022 - CRISPR (Clustered regularly interspaced short palindromic repeats) Therapeutics (Nasdaq: CRSP), a leading biopharmaceutical company specializing in the development of revolutionary gene-based treatments for severe illnesses, announced encouraging findings from their Phase 1 COBALT-LYM trial. The study assessed the safety and effectiveness of CTX130™, their proprietary allogeneic CAR-T cell therapy designed to target CD70, for the treatment of solid tumors and specific hematologic malignancies.

In April 2022, Metcela Inc. expanded its operations through the acquisition of Japan Regenerative Medicine Co., Ltd., a wholly-owned subsidiary of Kidswell Bio Co., Ltd. This strategic move enabled Metcela to broaden its product portfolio by incorporating JRM-001, an autologous cell product specifically designed for pediatric congenital heart disease. By integrating JRM-001 into its offerings, Metcela aimed to reinforce its clinical development infrastructure and accelerate the progress of these cutting-edge regenerative medicine solutions.

June 2022: Bristol Myers Squibb Company obtained U.S. FDA approval for Breyanzi, a CAR T cell therapy. It is specifically designed for patients with primary refractory or relapsed Large B-cell Lymphoma (LBCL) who are not eligible for transplant. This approval provides a promising treatment option for a subset of patients with limited alternatives.

June 2022: Avista Therapeutics entered into a partnership with F. Hoffmann La Roche Ltd to collaborate on the development of novel AAV gene therapy vectors for ocular diseases. This collaboration aims to leverage Avista’s expertise in gene therapy and Roche’s extensive capabilities in ocular disease research to advance innovative treatment options for patients with eye-related disorders.

January 2021: Integra LifeSciences acquired ACell, Inc. and its proprietary MatriStem UBM technologies. This strategic acquisition allowed Integra LifeSciences to expand its offerings in complex wound management solutions, providing more comprehensive treatment options for patients.

In April 2021, ExCellThera Inc., a clinical-stage company specializing in cell and molecular medicine, and Ossium Health, a therapeutics company focused on harnessing the potential of stem cell science for the treatment of blood and immune diseases, jointly announced a collaboration agreement. The purpose of this collaboration is to evaluate and explore opportunities to combine their respective capabilities, with the ultimate aim of advancing human health.